- Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial2018 | Second Faculty of Medicine
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival2010 | Faculty of Medicine in Hradec Králové
- A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis2014 | First Faculty of Medicine
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL2009 | Third Faculty of Medicine
- The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial2019 | Faculty of Medicine in Pilsen
- EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer2008 | Second Faculty of Medicine
- Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma2017 | First Faculty of Medicine
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma a randomised, double-blind phase III trial2007 | Faculty of Medicine in Hradec Králové
- Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non-Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy2010 | Third Faculty of Medicine
- Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial2018 | Faculty of Medicine in Hradec Králové
- Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial2023 | First Faculty of Medicine
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma a randomised, double-blind phase III trial2007 | First Faculty of Medicine
- Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma2023 | Central Library of Charles University
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial2020 | First Faculty of Medicine
- Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)2019 | Third Faculty of Medicine
- Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia2012 | First Faculty of Medicine
- Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)2010 | Third Faculty of Medicine
- AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial2023 | First Faculty of Medicine
- Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study2013 | First Faculty of Medicine
- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma2019 | Faculty of Medicine in Hradec Králové
- Cerebral near-infrared spectroscopy monitoring versus treatment as usual for extremely preterm infants: A protocol for the SafeBoosC randomised clinical phase III trial2019 | Publication without faculty affiliation
- A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)2022 | Third Faculty of Medicine
- Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial2023 | Faculty of Medicine in Hradec Králové
- A Randomized Phase III Trial Comparing Irinotecan (IRI) + 5FU/Folinic Acid (FA) to the Same Schedule of 5FU/FA in Patients (pts) with Metastatic Colorectal Cancer (MCRC) as Front Line Chemotherapy (CT)1999 | Publication without faculty affiliation
- A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer2008 | Third Faculty of Medicine
- Treatment of Large Cartilage Defects in the Knee by Hydrogel-Based Autologous Chondrocyte Implantation: Two-Year Results of a Prospective, Multicenter, Single-Arm Phase III Trial2022 | Second Faculty of Medicine
- Eribulin mesylate (Halaven(R)): a new hope for pretreated patients with advanced and metastatic breast cancer2015 | First Faculty of Medicine
- Gemcitabine plus cisplatin(GCis) versus gemcitabine plus carboplatin (GCcarb) in patients with stage IIIB and IV non-small cell lung cancer (NSCLC): a randomised phase-III trialPublication without faculty affiliation
- Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer2020 | First Faculty of Medicine
- Randomized phase III trial comparing bexarotene (L106949)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I2008 | Third Faculty of Medicine